ITEMS IN AFP WITH KEYWORD:
Mailed outreach significantly increases rates of colorectal cancer screening, with four tests needing to be mailed to screen one person.
Changes in cervical cancer screening and guidelines, human papillomavirus (HPV) vaccination recommendations, and colposcopy standards from the American Society for Colposcopy and Cervical Pathology have implications for all primary care clinicians. Cervical cancer prevention (with HPV vaccination), risk reduction (with smoking cessation counseling and support), screening, detection of precancerous cervical lesions, treatment, and post-treatment follow-up all can be performed by primary care clinicians.
It is important that primary care physicians have the ability and resources to identify women eligible for genetic counseling and testing for breast cancer.
Key clinical questions and their evidence-based answers directly from the journal's content, written by and for family physicians.
Feb 1, 2020 Issue
Breast Cancer Screening: ACP Releases Guidance Statements [Practice Guidelines]
The American College of Physicians reviewed guidelines from other organizations and developed four statements to provide advice to clinicians about breast cancer screening for women who are at average risk.
Adding ultrasonography to screening mammography in women younger than 50 years at low, intermediate, or high breast cancer risk is not associated with an increase in breast cancer detection. It is associated with increased unnecessary biopsy recommendations and results in more frequent follow-up.
The Prolaris test improves the accuracy of prognosis for patients with prostate cancer, especially those with low- or intermediate-grade disease who may be deciding between interventional and noninterventional treatment approaches.
This meta-analysis provides high-quality evidence that ﬂexible sigmoidoscopy and fecal occult blood testing both reduce the risk of death from colorectal cancer. The study did not provide a clear answer regarding a superior screening modality, so the decision to choose one test over another should b...
Jul 1, 2019 Issue
mSEPT9 (Epi proColon) Blood Test for Colorectal Cancer Screening [Diagnostic Tests: What Physicians Need to Know]
Epi proColon is a blood test used for the detection of the methylated septin 9 (mSEPT9) gene. It is approved by the U.S. Food and Drug Administration for colorectal cancer screening in people at average risk who have declined first-line screening tests.
A collaboration between AFP and the Lown Institute promotes a vision of delivering heath care that is based on the evidence, balanced in its approach, and focused on the patient.